Syndax Pharmaceuticals (SNDX) Citigroup’s Biopharma Back to School Summit 2026 summary
Event summary combining transcript, slides, and related documents.
Citigroup’s Biopharma Back to School Summit 2026 summary
10 Sep, 2026Commercial performance and market leadership
Achieved over $200 million annualized revenue in the second year of launch, with 85%+ market share in both NPM1 and KMT2A AML categories, supported by strong physician adoption and real-world data.
Six consecutive quarters of double-digit growth, with expectations for continued expansion as new patient starts and therapy duration increase.
Post-transplant maintenance is a key growth driver, targeting 70–80% of patients returning to therapy after transplant, with current transplant rates at about 50%.
Average therapy duration in relapse/refractory AML is tracking at 6–12 months, with some patients exceeding nine months post-transplant.
Pipeline development and clinical strategy
Two pivotal phase III frontline AML studies (EVOLVE-2 and REVEAL) are enrolling globally, targeting both fit and unfit patients, with dual primary endpoints including overall survival and response rates.
Additional innovative studies include RAVEN (alternative transplant approach) and MenTain (first randomized maintenance study), aiming to differentiate and expand clinical utility.
NUP98 AML subset is being targeted, with promising early data and plans for guideline submission.
Expansion into new indications and modalities
Axatilimab is advancing in idiopathic pulmonary fibrosis (IPF) with the MAXPIRe proof-of-concept study, designed for robust statistical rigor and expected to read out in Q4.
Axatilimab is also being evaluated in chronic GVHD, including a phase II Jakafi combination study and a pivotal phase III with dexamethasone, with data expected by year-end.
Subcutaneous formulation of axatilimab is in development to enhance patient convenience and franchise value.
Latest events from Syndax Pharmaceuticals
- Maintenance growth and frontline trials support a new phase of pipeline expansion.SNDX
Stifel 2026 Healthcare Conference 2026 - Earlier-line trials and maintenance dynamics are central to franchise expansion.SNDX
3rd Annual Guggenheim Healthcare Innovation Conference - Revenue rose 82% as Revuforj and Niktimvo grew and clinical programs advanced.SNDX
Q3 2026 - Strong commercial growth and pivotal trial catalysts highlight a transformative year ahead.SNDX
H.C. Wainwright 28th Annual Global Investment Conference - Q2 2026 revenue surged 92% YoY, driven by Revuforj and Niktimvo growth and pipeline progress.SNDX
Q2 2026 - Expanding pipeline and late-stage programs drive growth and value across major indications.SNDX
R&D Day 2026 - Rapid sales growth and pipeline expansion position for multi-billion dollar market leadership.SNDX
H.C. Wainwright 27th Annual Global Investment Conference - Two product launches target multi-billion dollar markets with robust early adoption and expansion plans.SNDX
TD Cowen 45th Annual Healthcare Conference - FDA approves Niktimvo for refractory chronic GVHD, with U.S. launch expected by early Q1 2025.SNDX
FDA Announcement